Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Su Pin Choo

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
Frontiers in Immunology|September 26, 2019
Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular CarcinomaJian Hang Lam, Harry Ho Man Ng, Chun Jye Lim, et al.
Nature Communications|February 28, 2017
The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinomaWeiwei Zhai, Tony Kiat-Hon Lim, Tong Zhang, et al.
Frontiers in Immunology|June 21, 2023
Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinomaChun Chau Lawrence Cheung, Yong Hock Justin Seah, Juntao Fang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" TrialWei Peng Yong, Sun Young Rha, Iain Bee-Huat Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2022
Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical TargetsFlorian Kocher, Alberto Puccini, Gerold Untergasser, et al.
Liver Cancer|July 8, 2016
National Cancer Centre Singapore Consensus Guidelines for Hepatocellular CarcinomaPierce K H Chow, Su Pin Choo, David C E Ng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2018
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i>-Mutated Hepatocellular CarcinomaHo Yeong Lim, Philippe Merle, Karl Heinz Weiss, et al.
Ebiomedicine|July 19, 2016
Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated CholangiocarcinomaKern Rei Chng, Sock Hoai Chan, Amanda Hui Qi Ng, et al.
Immunity|July 16, 2021
Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinomaYang Cheng, Bavani Gunasegaran, Harsimran D Singh, et al.
The Lancet. Oncology|December 16, 2021
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trialThomas Yau, Joong-Won Park, Richard S Finn, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Frontiers in Immunology|September 26, 2019
Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular CarcinomaJian Hang Lam, Harry Ho Man Ng, Chun Jye Lim, et al.
Nature Communications|February 28, 2017
The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinomaWeiwei Zhai, Tony Kiat-Hon Lim, Tong Zhang, et al.
Frontiers in Immunology|June 21, 2023
Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinomaChun Chau Lawrence Cheung, Yong Hock Justin Seah, Juntao Fang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" TrialWei Peng Yong, Sun Young Rha, Iain Bee-Huat Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2022
Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical TargetsFlorian Kocher, Alberto Puccini, Gerold Untergasser, et al.
Liver Cancer|July 8, 2016
National Cancer Centre Singapore Consensus Guidelines for Hepatocellular CarcinomaPierce K H Chow, Su Pin Choo, David C E Ng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2018
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i>-Mutated Hepatocellular CarcinomaHo Yeong Lim, Philippe Merle, Karl Heinz Weiss, et al.
Ebiomedicine|July 19, 2016
Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated CholangiocarcinomaKern Rei Chng, Sock Hoai Chan, Amanda Hui Qi Ng, et al.
Immunity|July 16, 2021
Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinomaYang Cheng, Bavani Gunasegaran, Harsimran D Singh, et al.
The Lancet. Oncology|December 16, 2021
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trialThomas Yau, Joong-Won Park, Richard S Finn, et al.
Pageof 10